240 related articles for article (PubMed ID: 15212862)
21. Risks associated with statin therapy: a systematic overview of randomized clinical trials.
Kashani A; Phillips CO; Foody JM; Wang Y; Mangalmurti S; Ko DT; Krumholz HM
Circulation; 2006 Dec; 114(25):2788-97. PubMed ID: 17159064
[TBL] [Abstract][Full Text] [Related]
22. [Fatal rhabdomyolysis caused by cerivastatin].
Scheen AJ
Rev Med Liege; 2001 Aug; 56(8):592-4. PubMed ID: 11584446
[TBL] [Abstract][Full Text] [Related]
23. Fatal rhabdomyolysis caused by lipid-lowering therapy.
Federman DG; Hussain F; Walters AB
South Med J; 2001 Oct; 94(10):1023-6. PubMed ID: 11702815
[TBL] [Abstract][Full Text] [Related]
24. Low-density lipoprotein cholesterol (LDL-C) levels and LDL-C goal attainment among elderly patients treated with rosuvastatin compared with other statins in routine clinical practice.
Harley CR; Gandhi S; Blasetto J; Heien H; Sasane R; Nelson SP
Am J Geriatr Pharmacother; 2007 Sep; 5(3):185-94. PubMed ID: 17996658
[TBL] [Abstract][Full Text] [Related]
25. Incidence of hospitalized rhabdomyolysis with statin and fibrate use in an insured US population.
Amend KL; Landon J; Thyagarajan V; Niemcryk S; McAfee A
Ann Pharmacother; 2011 Oct; 45(10):1230-9. PubMed ID: 21917557
[TBL] [Abstract][Full Text] [Related]
26. Meta-analysis of drug-induced adverse events associated with intensive-dose statin therapy.
Silva M; Matthews ML; Jarvis C; Nolan NM; Belliveau P; Malloy M; Gandhi P
Clin Ther; 2007 Feb; 29(2):253-60. PubMed ID: 17472818
[TBL] [Abstract][Full Text] [Related]
27. The withdrawal of Baycol (cerivastatin).
Griffin JP
Adverse Drug React Toxicol Rev; 2001 Dec; 20(4):177-80. PubMed ID: 11770168
[No Abstract] [Full Text] [Related]
28. [Cerivastatin and acute kidney failure caused by rhabdomyolysis].
Bravo JJ; Novoa D; Romero R; Sánchez-Guisande D
Nefrologia; 2001; 21(5):509. PubMed ID: 11795023
[No Abstract] [Full Text] [Related]
29. [Rhabdomyolysis, acute renal failure and use of cerivastatin combined with gemfibrozil. New evidence].
SantaCruz PL; González A; León ME; Fernández MY
Nefrologia; 2002; 22(3):301-2. PubMed ID: 12123135
[No Abstract] [Full Text] [Related]
30. Cerivastatin withdrawn from market.
Thompson CA
Am J Health Syst Pharm; 2001 Sep; 58(18):1685. PubMed ID: 11571807
[No Abstract] [Full Text] [Related]
31. Incidence of hospitalized rhabdomyolysis in patients treated with lipid-lowering drugs.
Graham DJ; Staffa JA; Shatin D; Andrade SE; Schech SD; La Grenade L; Gurwitz JH; Chan KA; Goodman MJ; Platt R
JAMA; 2004 Dec; 292(21):2585-90. PubMed ID: 15572716
[TBL] [Abstract][Full Text] [Related]
32. Rhabdomyolysis and cerivastatin: was it a problem of dose?
Kalaria D; Wassenaar W
CMAJ; 2002 Oct; 167(7):737. PubMed ID: 12389822
[No Abstract] [Full Text] [Related]
33. Bayer pulls cerivastatin (Baycol) from market.
Wooltorton E
CMAJ; 2001 Sep; 165(5):632. PubMed ID: 11563216
[No Abstract] [Full Text] [Related]
34. Cerivastatin and gemfibrozil-associated rhabdomyolysis.
Bruno-Joyce J; Dugas JM; MacCausland OE
Ann Pharmacother; 2001 Sep; 35(9):1016-9. PubMed ID: 11573847
[TBL] [Abstract][Full Text] [Related]
35. The safety of rosuvastatin in comparison with other statins in over 25,000 statin users in the Saskatchewan Health Databases.
García-Rodríguez LA; González-Pérez A; Stang MR; Wallander MA; Johansson S
Pharmacoepidemiol Drug Saf; 2008 Oct; 17(10):953-61. PubMed ID: 18425987
[TBL] [Abstract][Full Text] [Related]
36. Acute rhabdomyolysis associated with cerivastatin therapy.
Garcia-Valdecasas-Campelo E; Gonzalez-Reimers E; Lopez-Lirola A; Rodriguez-Rodriguez E; Santolaria-Fernandez F
Arch Intern Med; 2001 Mar; 161(6):893. PubMed ID: 11268236
[No Abstract] [Full Text] [Related]
37. Substituting for cerivastatin (Baycol).
Med Lett Drugs Ther; 2001 Sep; 43(1113):79-80. PubMed ID: 11581579
[No Abstract] [Full Text] [Related]
38. Risperidone and severe cerivastatin-induced rhabdomyolysis.
Giner V; Muñoz R; Redón J
J Intern Med; 2002 Feb; 251(2):177-8. PubMed ID: 11905593
[No Abstract] [Full Text] [Related]
39. Risk of hospitalized rhabdomyolysis associated with lipid-lowering drugs in a real-world clinical setting.
Cziraky MJ; Willey VJ; McKenney JM; Kamat SA; Fisher MD; Guyton JR; Jacobson TA; Davidson MH
J Clin Lipidol; 2013; 7(2):102-8. PubMed ID: 23415428
[TBL] [Abstract][Full Text] [Related]
40. Cerivastatin, genetic variants, and the risk of rhabdomyolysis.
Marciante KD; Durda JP; Heckbert SR; Lumley T; Rice K; McKnight B; Totah RA; Tamraz B; Kroetz DL; Fukushima H; Kaspera R; Bis JC; Glazer NL; Li G; Austin TR; Taylor KD; Rotter JI; Jaquish CE; Kwok PY; Tracy RP; Psaty BM
Pharmacogenet Genomics; 2011 May; 21(5):280-8. PubMed ID: 21386754
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
